UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil

doi:10.3748/wjg.v18.i45.6635

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8528)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

582

HTML

7539

Figures (1-4)

215

Tables (1-4)

192

Sum=8528

Dec 7, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2012; 18(45): 6635-6644
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6635

Full Size Figure Download Figure

Figure 3 Time to progression and overall survival according to UDP-glucuronosyltransferase1A1*28 genotypes. A: Time to progression (TTP): Patients with TA6/6 were 5.97 (95%CI: 3.85-8.09), patients with TA6/7 and TA7/7 were 4.00 (95%CI: 1.15-6.85), P = 0.154; B: Overall survival (OS): Patients with TA6/6 were 18.00 (95%CI: 10.77-25.23), patients with TA6/7 and TA7/7 were 14.90 (95%CI: 7.58-22.22), P = 0.444. No significant difference was found between TA6/6 (wild type) and mutated genotypes. UGT1A1: UDP-glucuronosyltransferase1A1.

Citation: Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 2012; 18(45): 6635-6644
URL: https://www.wjgnet.com/1007-9327/full/v18/i45/6635.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i45.6635